Company profile
BrightSens Diagnostics
Disruptive Technology for Molecular Diagnostics based on Ultrabright Fluorescent Nanoparticles
- Industry
- Biotechnology Research
- Employees
- 6
- Headquarters
- Strasbourg
- Founded
- 2022
- Office locations
- 1
BrightSens Diagnostics company summary
BrightSens Diagnostics is a company in the Biotechnology Research industry, headquartered in Strasbourg, founded in 2022. On LinkedIn the company has around 6 employees.
What technology does BrightSens Diagnostics use?
No technologies detected yet. Warmrank rechecks company websites on a rolling basis.
About BrightSens Diagnostics
The current limitations of molecular diagnostics, such as PCR, do not allow for rapid screening and personalized follow-up of cancers and viral diseases. Healthcare professionals and institutions are therefore looking for simple, rapid and cost-effective tests for screening and monitoring patients. BrightSens Diagnostics will provide the solution to these needs by offering highly sensitive Point of Care tests. Our patented technology, with unique properties, is the result of 10 years of research supported by 2 ERC contracts with over 2M Euros. Our ultra-bright and ultra-sensitive fluorescent NanoAntennas amplify a detection signal. They allow direct measurement of very low concentrations of RNA - disease biomarkers - without enzymes, by simple fluorescence measurement. Our Point of Care tests will revolutionize molecular diagnostics.
Where is BrightSens Diagnostics located?
BrightSens Diagnostics lists 1 location.
Compare companies similar to BrightSens Diagnostics
More companies in Biotechnology Research.
| Company | Industry | Employees | Founded | Headquarters |
|---|---|---|---|---|
BrightSens Diagnostics brightsens-diag.com | Biotechnology Research | 6 | 2022 | Strasbourg |
 Thermo Fisher Scientific thermofisher.com | Biotechnology Research | 100,779 | - | Waltham, MA |
 Amgen amgen.com | Biotechnology Research | 41,028 | 1980 | Thousand Oaks, CA |
 Biogen biogen.com | Biotechnology Research | 7,742 | - | Cambridge, MA |
 Biocon biocon.com | Biotechnology Research | 11,902 | - | Bangalore, Karnataka |
| Biotechnology Research | 28,679 | - | Bethesda, MD | |
 Genentech gene.com | Biotechnology Research | 18,296 | 1976 | South San Francisco, California |
 Eurofins eurofins.com | Biotechnology Research | 24,928 | - | Luxembourg, Luxembourg |
 Gilead Sciences gilead.com | Biotechnology Research | 14,743 | - | Foster City, CA |
 Syneos Health syneoshealth.com | Biotechnology Research | 23,772 | - | Morrisville, NC |
 Moderna modernatx.com | Biotechnology Research | 6,238 | 2010 | Cambridge, Massachusetts |
Frequently asked questions about BrightSens Diagnostics
What does BrightSens Diagnostics do?
The current limitations of molecular diagnostics, such as PCR, do not allow for rapid screening and personalized follow-up of cancers and viral diseases. Healthcare professionals and institutions are therefore looking for simple, rapid and cost-effective tests for screening and monitoring patients. BrightSens Diagnostics will provide the solution to these needs by offering highly sensitive Point of Care tests. Our patented technology, with unique properties, is the result of 10 years of research supported by 2 ERC contracts with over 2M Euros. Our ultra-bright and ultra-sensitive fluorescent NanoAntennas amplify a detection signal. They allow direct measurement of very low concentrations of RNA - disease biomarkers - without enzymes, by simple fluorescence measurement. Our Point of Care tests will revolutionize molecular diagnostics.
How many employees does BrightSens Diagnostics have?
BrightSens Diagnostics has around 6 employees on LinkedIn.
Where is BrightSens Diagnostics headquartered?
BrightSens Diagnostics is headquartered in Strasbourg.
When was BrightSens Diagnostics founded?
BrightSens Diagnostics was founded in 2022.
Build a lead list from companies like BrightSens Diagnostics
Describe your ICP or import a CSV. Warmrank finds matching companies, enriches contacts with verified emails, and tracks every lead.